2023

1

2

3

4

5

6

1/2

® **PD-1**

2023 **2.5**

MSI-H

sqNSCLC ES-SCLC

SCLC FDA EC

ES-SCLC MAA

EMA

1Q23

	1Q23	1Q22*	YoY
	108.71	103.85	*4.7%*
	9.87	4.57	*116.2%*
	9.19	8.01	*14.8%*
	8.73	8.56	*2.1%*
	9.69	8.10	*19.7%*
	0.37	0.18	*105.6%*

	1Q23	1Q22*
	51.3%	43.6%
	23.1%	19.9%
	9.1%	7.6%
	8.9%	7.8%
	2.4%	1.0%
	28.2%	23.6%

	1Q23	2022
	154.73	162.41

1

2

3

1

2

BNTX

2

-3.44

BNTX 2022

0.68

4.12

1

2

2022

2022

	2022	2021	YoY
	439.52	390.11	*12.7%*
	37.31	47.29	*-21.1%*
	38.73	32.77	*18.2%*
	42.18	39.38	*7.1%*
	58.85	49.78	*18.2%*
	43.02	38.37	*12.1%*
	1.43	1.85	*-22.7%*
( )	30%	30%	-

-1.42 15.93 ,

BNTX BNTX

-10

37.31 21.10%

2022	2021
47.3%	48.1%
20.9%	23.3%
8.7%	8.3%
9.8%	9.8%
1.5%	1.2%
26.4%	24.8%

1

2)

3

2.96

1

2

3

2022	2021
162.41	103.17
445.82	391.96
1.06	1.04
0.85	0.85
49.5%	48.2%

A

2022 7 A 44.8

1

2

3


1
2
3
4
5
DRG/DIP

	® PD-1 *MSI-H*	® CAR-T
	® CD20	® HER2
	®	®
	®	®
		® -
	BNT162b2	
	Vero	
	2022 27 / /	

	® PD-1	® HER2 -	® CAR-T
	Opicapone COMT		RT002 *GL*
	®		Parsabiv
	® PD-1	FCN-1502 HER2-ADC	FCN-437 CDK4/6
	SAF-189 ALK&ROS1		Tenapanor NHE3 *ESRD-HD*
	FCN-338 Bcl-2 *R/R BCL*		HLX208 BRAF V600E *LCH ECD*
	FCN-159 MEK *I*		ET-26
	- *DU RE*		FKC-889 CAR-T
	III 13		*I* 24
	NDA		*NDA*
	2022 30 2022		NDA 118 21

1 2023 3 31
2 2023 3 31

3

&


1994
2002-2004
2008-2010
2013
2017
2018-2019
2020
2021
2022
Alma
Alma
Gland Pharma
Tridem Pharma
Gland Pharma
Tridem Pharma
Intuitive Surgical
Kite Pharma
RT002
mRNA
Cenexi
Akynzeo
Aloxi
Anamorelin
Gland Pharma
CDMO
Parsabiv®

2022

1/2

Gland Pharma 2.1 **Cenexi**

CDMO



5

2022

ICRC

Gland Pharma

2023 2

Gland Pharma

CDMO

CDMO ,2023

4 **Cenexi**

5

16 GPO

PD-1 11

ES-SCLC

Syneos Health PD-1

2022 **Sisram** **1.4**

28.2% Sisram **40.5%**

GS(2016)1666

2/2



MSCI-ESG



2022 10

A

E nvironment

EHS

EHS

2021-2026 EHS

2022 115.36

337,806 3.2%

S ocial

5,600

G overnance

ESG

ESG

10



1



2



/ADC

RNA

1

2

BNTX

2022

55.22 26%[1]
+39.44% YoY

® HER2 ®
®
TNF-
PD-1 ®
®

85.82 40%[1]
-0.45% YoY

mRNA
®
®

28.83 13%[1]
-0.24% YoY

®
®

21.15 10%[1]
+6.12% YoY

10.03 5%[1]
-11.79% YoY

®

12.48 6%[1]
+9.96% YoY

1

2022 **50.97**

+13.62% YoY

85%

16.54% 35.52

11.53%

30%

2022

260

2022 249

16 PCT

17 48



SCLC **PD-1**

2023Q1 **2.5**

ES-SCLC

OS

OS 15.4

10.9 24 43.1% 7.9%

JAMA Nature Medicine

British Journal of Cancer

PD-1

MSI-H

27 110 30%

400

SCLC FDA EC

DTP

2022



2022

	10	5	mRNA ® HER2 ® CD20 ®
5	10	3	® ®
3	5	8	® PD-1 ® VERO ® ® 8
1	3	31	® TNF- ® ® ® 31


5,938
17.03% YoY
6,949
2021
2022


826
-36.9% YoY
521
2021
2022


2022
20.5% YoY
354.5
294.3
2021
2022
(USD million)
23.2% YoY
32.5
40.1


2021 7
100%
Copulla

2017

2019

2020

2021

2022

2016
2017

Xi

200 800

31.2

Intuitive Surgical

1,700
4,000

2022 55
300

10

2000 FDA 2022 12 31
7,544 55,000
1,000

Ion

2019 Ion
FDA

2021 10 Ion

Ion

&

>15%

2022 6 F-C800p

2021

F-i3000

FCi

2022 4


同口径增长
47.64% YoY
2022

6,333

JCI

JVF

佛山禅医院 JCI国际认证医院

1,750

2022 21.45 1.11

86.47%

深圳恒生医院 SHENZHEN HENGSHENG HOSPITAL

600

2017 11 9.09

60%

800

900

2022 1 70%

宿迁市钟吾医院 SUQIAN ZHONGWU HOSPITAL 宿迁市肿瘤医院 SUQIAN CANCER HOSPITAL

卓尔芸 JOYFUL WAY

安徽济民肿瘤医院 ANHUI JIMIN CANCER HOSPITAL

温州老年病医院 WENZHOU GERIATRIC HOSPITAL

湖北省人民医院 武汉济和医院

STAR HOSPITAL 星晨妇儿 上海复星医疗旗下高品质医院 医保定点医院

*

2022 12

2021

10

FHMO

-
-
-
-



-
-
- /
-


6.0% YoY
521,051
552,148
2021
2022


7,759
8,526
2021
2022

1/2

			/		IND	1	2	3	NDA
	HLX10[1]	+	PD-1		III 2022 11				
					2022 11		2022 FDA/EC	2023 1	
					III 2023 1		2022 5		
				/					
		+	PD-1+VEGF						
		+HLX07	PD-1+EGFR						
					2022 1				
	HLX04-O[2]		VEGF		2022 2 III				
	HLX22	+	HER2+HER2						
	HLX07		EGFR						
	HLX11	[3]	HER2		III 2022				
	HLX05	[4]	EGFR						
	HLX02	[5]	HER2		FDA 2020				

1 KG Bio 10 2

3 Organon 4

5 Accord Cipla Jacobson mAbxience Eurofarma Abbott 6 2023 4 28

2/2

		/		IND	1	2	3	NDA
	FS-1502	HER2	HER2					
			HER2					
	FS-1502+	HER2+PD-1	HER2					
	HLX14 [1]	RANKL						
	HLX26	LAG-3						
	HLX35[2]	EGFR 4-1BB						
	HLX301	PD-L1 TIGIT						
	HLX15	CD38						
	HLX13	CTLA-4						
		EPO						
		INSR						
		50R INSR						
		GLP-1						
	RT002		GL					
			CD					

2023 4 28

1/2

		/		IND	1	2	3	NDA
	FCN-437c	CDK4/6	(1L)	2022 1 NMPA III I				
			(2L)	2022 1 III				
	SAF-189	ALK		2022 1 NMPA III I				
		ROS1						
	HLX-208	BRAF V600E	LCH ECD	2023 4 NMPA	2022 1 NMPA Ib/II			
	FCN-159	MEK	I					
				2022 5 NMPA				
				2023 4 NMPA	2022 5 NMPA			
				2023 3 NMPA II				
				2023 3 NMPA II				
	YP01001	VEGFR						
	FCN-338	BCL-2		2023 3 NMPA II				
				I				
			B					
	FH-2001	FGFR/PD-L1						

2023 4 28

2/2

		/		IND	1	2	3	NDA
		TPO-R	ITP					
	Tenapanor	NHE 3	(ESRD-HD)					
		-						
	Tenapanor	NHE 3	(IBS-C)					
	FCN-342	URAT1						
	Molnupiravir	RNA						
	Paxlovid	3CL						
	BNT162b2	-						
	PA-824	-	/ XDR-TB MDR-TB					
	Opicapone	COMT						
	Fortacin	-						
	ET-26	-						

2023 4 28

			IND	1	2	3	NDA
	/						
	/						
	/						
13							
24							
23							
	-						

2023 4 28

LOGO

Fosun Pharma, the Representor or the Provider will not warrant the accuracy, the completeness and the timeliness of all information and contents, including predictive description, contained in the PPT documents/visual materials. In the event of any mistake, omission, and inaccuracy, Fosun Pharma, the Representor or the Provider should not be held for any liabilities in this regard.

The PPT documents/visual materials will not include and should not be deemed as any investment proposals. The investor should take their own responsibilities for any determinations so come to based upon the information contained in the PPT documents/visual materials.

Fosun Pharma is entitled to all rights, including copyright, pertaining to the PPT documents/visual materials. The characters, the designs and Fosun , are the trade name, trademark and the logos legally owned by Fosun Pharma. Without written consent offered by Fosun Pharma, any third party should not utilize such materials and information in any manner, including reprinting.

www.fosunpharma.com